Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Is AbbVie Stock Underperforming the Dow?

North Chicago, Illinois-based AbbVie Inc. (ABBV) is a biopharmaceutical company that researches, develops, manufactures, commercializes, and sells medicines and therapies. Valued at a market cap of $397.3 billion, the company primarily concentrates on key therapeutic areas, including immunology, oncology, neuroscience, eye care, and aesthetics.

Companies worth $200 billion or more are typically classified as “mega-cap stocks,” and AbbVie fits the label perfectly, with its market cap exceeding this threshold, underscoring its size, influence, and dominance within the drug manufacturers - general industry. The company’s key strengths lie in its strong specialty drug portfolio, deep research and development capabilities, and diversified therapeutic...

Fundamentals

See More
  • Market Capitalization, $K 405,579,520
  • Shares Outstanding, K 1,767,385
  • Annual Sales, $ 61,160 M
  • Annual Income, $ 4,226 M
  • EBIT $ 15,075 M
  • EBITDA $ 24,061 M
  • 60-Month Beta 0.35
  • Price/Sales 6.50
  • Price/Cash Flow 15.06
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 27.69% (-0.17%)
  • Historical Volatility 23.18%
  • IV Percentile 66%
  • IV Rank 28.12%
  • IV High 51.27% on 04/08/25
  • IV Low 18.46% on 08/22/25
  • Expected Move (DTE 2) 4.46 (1.95%)
  • Put/Call Vol Ratio 0.81
  • Today's Volume 9,091
  • Volume Avg (30-Day) 14,056
  • Put/Call OI Ratio 0.88
  • Today's Open Interest 215,255
  • Open Int (30-Day) 221,297
  • Expected Range 223.98 to 232.90

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 30 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 3.01
  • Number of Estimates 9
  • High Estimate 3.17
  • Low Estimate 2.97
  • Prior Year 2.46
  • Growth Rate Est. (year over year) +22.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
204.27 +11.83%
on 02/04/26
235.25 -2.89%
on 02/17/26
+9.18 (+4.19%)
since 01/23/26
3-Month
204.27 +11.83%
on 02/04/26
237.04 -3.63%
on 01/07/26
-1.07 (-0.47%)
since 11/24/25
52-Week
164.39 +38.96%
on 04/09/25
244.81 -6.69%
on 10/01/25
+24.36 (+11.94%)
since 02/24/25

Most Recent Stories

More News
Is AbbVie Stock Underperforming the Dow?

Although AbbVie has lagged behind the Dow recently, analysts remain moderately optimistic about the stock’s prospects.

$DOWI : 49,174.50 (+0.76%)
ABBV : 228.44 (-0.45%)
PFE : 27.14 (+0.30%)
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference

NORTH CHICAGO, Ill. , Feb. 24, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate...

ABBV : 228.44 (-0.45%)
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States

NORTH CHICAGO, Ill. , Feb. 23, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced a new $380 million investment to build two new active pharmaceutical ingredient (API) manufacturing facilities...

ABBV : 228.44 (-0.45%)
1 Cash-Producing Stock to Target This Week and 2 We Ignore

1 Cash-Producing Stock to Target This Week and 2 We Ignore

VRNS : 21.71 (+2.99%)
DBX : 24.28 (-0.90%)
ABBV : 228.44 (-0.45%)
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

NORTH CHICAGO, Ill. , Feb. 20, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for...

ABBV : 228.44 (-0.45%)
AbbVie Declares Quarterly Dividend

NORTH CHICAGO, Ill. , Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.73 per share. 

ABBV : 228.44 (-0.45%)
1 Mega-Cap Stock on Our Watchlist and 2 We Avoid

1 Mega-Cap Stock on Our Watchlist and 2 We Avoid

JPM : 297.30 (-0.12%)
ORCL : 146.14 (+3.42%)
ABBV : 228.44 (-0.45%)
The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call

The 5 Most Interesting Analyst Questions From AbbVie’s Q4 Earnings Call

ABBV : 228.44 (-0.45%)
Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market

EQNX::TICKER_START (NASDAQ:HELP),(NYSE:JNJ),(NYSE:ABBV),(NYSE:TAK),(NYSE:AZN) EQNX::TICKER_END

HELP : 7.37 (+9.51%)
AZN : 206.61 (+0.81%)
JNJ : 246.28 (+0.71%)
HELP.NE : 9.9600 (+7.10%)
ABBV : 228.44 (-0.45%)
TAK : 18.65 (-0.80%)
3 Market-Beating Stocks to Research Further

3 Market-Beating Stocks to Research Further

CCB : 78.90 (+4.30%)
BX : 116.41 (+2.37%)
ABBV : 228.44 (-0.45%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 233.33
2nd Resistance Point 232.04
1st Resistance Point 230.24
Last Price 228.44
1st Support Level 227.15
2nd Support Level 225.87
3rd Support Level 224.07

See More

52-Week High 244.81
Last Price 228.44
Fibonacci 61.8% 214.09
Fibonacci 50% 204.60
Fibonacci 38.2% 195.11
52-Week Low 164.39

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar